MedTech mergers and acquisitions took an unexpected turn on 4 November 2026, when Smith+Nephew confirmed that its discussions with Johnson & Johnson have ended. The company said it approached J&J earlier in 2026 as part of a review of options for its Orthopaedics business, gave no reason for the end of talks and said it will keep exploring strategic options. On the same day it cut its 2026 guidance for the second time this year. Press reports said the talks collapsed over a leadership disagreement, which neither company has confirmed. This business analysis looks at what is known, what the numbers imply and what could come next. It is not investment advice.
Key takeaways on MedTech mergers and acquisitions at Smith+Nephew
- Smith+Nephew confirmed the approach to J&J and that talks have ended; no reason was given.
- A reported leadership disagreement is not confirmed by either company.
- Guidance now: underlying revenue growth about 3% (from about 4%), trading profit about $1.25 billion (from about $1.3 billion), free cash flow about $750 million (from about $800 million).
- The earlier cut in August lowered growth guidance from about 6% to about 4%.
- Orthopaedics grew only 2.5% in Q3 and is about 38% of revenue by our calculation.
What was confirmed
The company confirmed that it approached Johnson & Johnson, that discussions took place and have ended, and it acknowledged press comment about a possible combination with J&J’s DePuy Synthes. It did not disclose terms, structure or valuation. The chief executive, Deepak Nath, said Orthopaedics is not where the company wants it to be. The company also said it will continue to actively explore the full range of strategic options, which leaves open a sale, a partnership, a spin-off or an operational fix, though it named none of these.
Why the numbers matter to any transaction
| Metric | Q3 2026 |
|---|---|
| Group revenue | $1,551 million, up 3.4% underlying |
| Orthopaedics revenue | $590 million, up 2.5% |
| Sports Medicine and ENT | $507 million, up 7.9% |
| Advanced Wound Management | $454 million, down 0.2% |
| US revenue | $812 million, up 3.0% |
| US knees | Down 7.3% |
| US hips | Down 1.0% |
A buyer or partner for Orthopaedics would examine growth, margin and the US trend. The unit is growing slower than the group, and US knees are falling, which is the area the company blames for the guidance cut. Outside the US, knees grew 4.0% and hips 6.0%. These facts do not determine value, but they illustrate why a seller would want to review options and why price could be contested.
The guidance path
| Date | Underlying growth guide | Trading profit guide |
|---|---|---|
| Early 2026 | About 6% | Not stated here |
| August 2026 | About 4% | About $1.3 billion |
| 4 November 2026 | About 3% | About $1.25 billion |
Trading profit growth guidance fell from about 8% to about 4% in the latest update, and adjusted return on invested capital is now expected at about 9% excluding Integrity Orthopaedics, against a previous target above 10%. Integrity Orthopaedics is expected to be marginally dilutive in 2026 and accretive from 2028. A $500 million buyback is under way, with $250 million complete.
Possible paths from here (our framing, not forecasts)
- Operational fix: new products such as the LANDMARK cementless knee, cleared by the FDA in September 2026, and commercial changes, aimed at stabilising US hips and knees.
- Another transaction: talks with a different counterparty or a separation of the unit, though the company has named nothing.
- Status quo: continued review while results develop.
We assign no probabilities. Any of these would take time, and the company has not set a timetable.
The leadership claim
Press reports said the talks ended over a disagreement about leadership. Neither Smith+Nephew nor J&J has confirmed this, and Smith+Nephew gave no reason. We include the claim only to explain why the question is being asked, and readers should not treat it as established.
Timeline
- Earlier in 2026: approach to J&J.
- August 2026: guidance cut to about 4%.
- September 2026: LANDMARK knee cleared.
- 4 November 2026: talks ended; guidance cut to about 3%.
- 1 March 2027: full-year results.
Market context
According to Acumen Research And Consulting, the global orthopaedic devices market is projected to reach about USD 81.3 billion by 2027, at about 5% a year from 2020, implying a base of roughly USD 58 billion in 2020 by our calculation. North America holds a large share, Europe is second and Asia-Pacific is the fastest-growing region. The report was last updated in May 2020 and has garbled descriptions, so it is dated and indicative only, and it does not value any company or deal.
Our analysis
In our assessment, the end of the talks leaves Smith+Nephew with the same problem it had before: an Orthopaedics unit growing slowly and weak in the US. The strategic review continues, and the second guidance cut raises the stakes for the fourth quarter. We make no forecast of any deal or share price.
What is not disclosed
- Why the talks ended and on what terms.
- Other parties, if any, in discussions.
- The timetable for the strategic review.
- Margin by segment.
Risks and caveats
- Reports of a leadership dispute are unconfirmed.
- Guidance is a company expectation.
- Market data are dated.
- This article is not investment advice.
What to watch next
- Updates on the Orthopaedics review.
- Fourth-quarter US hip and knee trends.
- Full-year results on 1 March 2027.
- Competitor and peer deal activity.
General background
Related coverage: a CDMO-driven results story. Company information is on the Smith+Nephew website and the Johnson & Johnson website. More in the medical devices section.
Questions readers are asking about MedTech mergers and acquisitions
Did Smith+Nephew and J&J agree a deal?
No. The company confirmed talks took place and have ended.
Why did the talks end?
No reason was given.
Is Smith+Nephew still looking at options?
Yes. It says it will continue to explore the full range of strategic options.
FAQ
What is trading profit?
The company’s operating profit measure before certain items.
What is ROIC?
Return on invested capital.
What is DePuy Synthes?
Johnson & Johnson’s orthopaedics business.
How we reported this: details come from Smith+Nephew’s third-quarter trading update of 4 November 2026 and press reports; reports of a leadership dispute are unconfirmed; market figures are attributed to Acumen Research And Consulting; calculations marked as ours are our own. Last updated 5 November 2026. This is news reporting and not investment advice.
